Xencor (NASDAQ:XNCR) Shares Break Above 50 Day Moving Average - What's Next?

Key Points

• Xencor shares rose 15.9% and traded above their 50-day moving average, reaching $33.60 before last trading at $29.18.
• Updated Phase 1 data for kidney-cancer therapy XmAb819 showed a 45.5% response rate; Xencor selected a dose and plans to advance the program into late-stage testing, boosting expectations for its commercial potential.
• Analysts maintain a generally positive outlook, with an average “Moderate Buy” rating and a $35.11 price target, though XmAb819’s results remain early-stage and require validation in larger trials.

Xencor, Inc. (NASDAQ:XNCR - Get Free Report)'s share price passed above its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $25.42 and traded as high as $33.60. Xencor shares last traded at $29.18, with a volume of 8,896,092 shares changing hands.

Key Xencor News

Here are the key news stories impacting Xencor this week:

• Positive Sentiment: Updated Phase 1 data showed a 45.5% response rate in the kidney-cancer study, with reports describing the treatment’s antitumor activity as “impressive,” “profound,” or “unprecedented.” The results substantially improved investor expectations for XmAb819’s commercial potential. Xencor Shares Rise Pre-Bell After Kidney Cancer Trial Shows 45.5% Response Rate
• Positive Sentiment: Xencor selected a Phase 1 dose and said it plans to advance XmAb819 into a late-stage trial, providing a clearer development path for the program. Xencor Presents Phase 1 Dose Selection Data for XmAb819
• Positive Sentiment: Analyst commentary highlighted the possibility of an FDA accelerated-approval pathway if subsequent studies confirm the early efficacy signal, adding to the bullish sentiment around XNCR. Xencor Strong Buy Potential for FDA Accelerated Approval Pathway
• Neutral Sentiment: The results are from an early-stage study, so the response rate will need validation in larger, later-stage trials. Xencor remains a clinical-stage company with substantial development and regulatory risk.
• Neutral Sentiment: A reported October short-interest figure of zero shares implies no measurable short-covering catalyst, although the data appears inconsistent with the claim of a significant increase in short interest.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on XNCR. Raymond James Financial upped their price target on shares of Xencor from $40.00 to $46.00 and gave the stock a "strong-buy" rating in a research report on Tuesday, September 1st. Wall Street Zen upgraded shares of Xencor from a "strong sell" rating to a "hold" rating in a research report on Saturday, August 8th. Truist Financial reaffirmed a "buy" rating and issued a $29.00 target price (up from $27.00) on shares of Xencor in a research note on Monday, September 28th. Wells Fargo & Company started coverage on shares of Xencor in a research report on Wednesday, September 30th. They set an "overweight" rating and a $55.00 target price on the stock. Finally, Barclays set a $45.00 price target on shares of Xencor and gave the company an "overweight" rating in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Xencor presently has an average rating of "Moderate Buy" and an average price target of $35.11.

Xencor Trading Up 15.9%

The company has a 50 day moving average price of $25.42 and a 200 day moving average price of $16.66. The company has a market capitalization of $2.17 billion, a price-to-earnings ratio of -13.45 and a beta of 0.89.

Xencor (NASDAQ:XNCR - Get Free Report) last released its earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, topping analysts' consensus estimates of ($0.80) by $0.51. Xencor had a negative return on equity of 28.66% and a negative net margin of 155.59%. The company had revenue of $51.22 million during the quarter, compared to the consensus estimate of $18.89 million. During the same quarter in the previous year, the company posted ($0.41) earnings per share. The firm's quarterly revenue was up 17.4% on a year-over-year basis. Equities analysts predict that Xencor, Inc. will post -3.05 earnings per share for the current year.

Institutional Trading of Xencor

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Seven Fleet Capital Management LP acquired a new stake in shares of Xencor during the 2nd quarter worth approximately $7,828,524,000. BlackRock Inc. bought a new stake in shares of Xencor during the second quarter worth approximately $219,785,000. Primecap Management Co. CA acquired a new position in Xencor in the second quarter valued at approximately $163,919,000. Legal & General Group Plc acquired a new position in Xencor in the second quarter valued at approximately $17,568,000. Finally, Dimensional Fund Advisors LP lifted its holdings in Xencor by 3.6% in the first quarter. Dimensional Fund Advisors LP now owns 1,294,887 shares of the biopharmaceutical company's stock valued at $15,613,000 after buying an additional 45,599 shares during the period.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company headquartered in Monrovia, California. Founded in 1997, the company develops engineered antibodies and other biologic medicines for the treatment of cancer, autoimmune disorders and other serious diseases.

Xencor's research is centered on its XmAb technology platform, which is designed to modify antibodies to improve their therapeutic properties or create new antibody-based mechanisms. The platform supports the development of bispecific antibodies, immune-cell engagers and antibodies with extended activity in the body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.